NetScientific PLC Executed Warrants
16 December 2016 - 6:00PM
RNS Non-Regulatory
TIDMNSCI
NetScientific PLC
16 December 2016
("NetScientific" or the "Company" or the "Group")
NetScientific Executed Warrants in Portfolio Company, PDS
Biotechnology, a new paradigm in cancer immunotherapy
London, UK - 16 December 2016 - NetScientific plc
("NetScientific", AIM:NSCI), the transatlantic healthcare IP
commercialisation group, announces that it has exercised warrants
for 1,387,480 shares in its portfolio company, PDS Biotechnology.
The total price for these shares was $687,492.68.
PDS is a clinical stage immuno-oncology company committed to the
development of potent and safe immunotherapies which alter tumour
immunology to enable superior killer T-cell attack. The Company has
developed the Versamune(R) T-cell activating platform, the first
immuno-oncology technology to successfully combine the three
critical attributes of effective immunotherapies in a simple
nanoparticle, whilst also eliminating the potentially debilitating
toxicities of some of the leading immunotherapy approaches. PDS's
oncology pipeline includes compounds for prostate, ovarian, breast
and colorectal cancers, in addition to its lead PDS0101 program for
several HPV-related cancers. With positive phase I/IIa trial data,
PDS has agreed partnership funding from the National Institute of
Health and MD Anderson for three phase II clinical trials.
NetScientific has now invested a total of $3.5m for a
shareholding in PDS Biotechnology of 14.6%, on a fully diluted
basis.
- Ends -
For more information, please contact:
NetScientific Tel: +44 (0)20 3514
François R. Martelet, 1800
M.D., CEO
Ian Postlethwaite, CFO
Stifel Nicolaus Europe Limited Tel: +44 (0) 20 7710
(NOMAD and broker) 7600
Jonathan Senior / David
Arch / Ben Maddison
Consilium Strategic Communications Tel: +44 (0)20 3709
Mary-Jane Elliott / Jessica 5700
Hodgson / Chris Welsh netscientific@consilium-comms.com
About NetScientific Plc
NetScientific is a transatlantic healthcare IP commercialisation
group focused on improving the health and well-being of people with
chronic diseases.
For more information, please visit the website at
www.netscientific.net.
About the Versamune(R) T-Cell Activating Platform:
Versamune(R) is a synthetic T-cell activating nanotechnology
that overcomes a key obstacle facing cancer immunotherapy by
facilitating efficient access of cancer protein antigens to
pathways that enable their effective presentation to killer
T-cells. This process trains the body's T-cells to recognise and
efficiently attack the cancer. The ingredient of the Versamune(R)
platform has also been proven to activate critical immunological
signalling pathways that result in the safe production of
immunological proteins known as cytokines and chemokines locally
within the lymph nodes to recruit T-cells, and enhance T-cell
proliferation as well as the killing activity of T-cells.
Activation of these immunological pathways may also be responsible
for the ability of the Versamune(R) -based immunotherapies to
reduce the population of immune suppressive cells and to facilitate
the killing activity of the T-cells specifically within the
tumours.
Contact Details
PDS Biotechnology Corp.
Frank Bedu-Addo, Ph.D., CEO
Michael King, M.B.A., CFO
Phone: +1-732-640-0145
Email: Execinfo@pdsbiotech.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRALIFIRFRLRLIR
(END) Dow Jones Newswires
December 16, 2016 02:00 ET (07:00 GMT)
Netscientific (LSE:NSCI)
Historical Stock Chart
From Apr 2024 to May 2024
Netscientific (LSE:NSCI)
Historical Stock Chart
From May 2023 to May 2024